Module 1: HER2-Positive Breast Cancer

Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19. Abstract

Baselga J et al. A Phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of placebo + trastuzumab + docetaxel vs pertuzumab + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA). Proc SABCS 2011;Abstract S5-5.

Gianni L et al. AVEREL, a randomized Phase III trial to evaluate bevacizumab in combination with trastuzumab + docetaxel as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Proc SABCS 2011;Abstract S4-8.

Goss P et al. Results of the TEACH trial. Lapatinib in women with early-stage HER2-overexpressing breast cancer: A double-blind, placebo-controlled, Phase III trial. Proc SABCS 2011;Abstract S4-7.

Jones S et al. Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab (HER TC) in HER2 positive early stage breast cancer patients. Proc SABCS 2011;Abstract PD07-03.

Von Minckwitz G et al. Adjuvant Pertuzumab and Herceptin IN Initial TherapY in breast cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). Proc SABCS 2011;Abstract OT1-02-04.

Yardley DA et al. Phase II study evaluating lapatinib in combination with nab^®-paclitaxel in women who have received ≤1 chemotherapy regimen for HER2-overexpressing metastatic breast cancer. Proc SABCS 2011;Abstract P1-12-10.

Module 2: Multigene/Biomarker Assays

Gonzalez-Angulo AM et al. SWOG S1007: A Phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with Recurrence Score (RS) of 25 or less. Proc SABCS 2011;Abstract OT1-03-01.

Rezai M et al. Impact of the Recurrence Score on adjuvant decision-making in ER-positive early breast cancer — Results of a large prospective multicentre decision impact study in node negative and node positive disease. Proc SABCS 2011;Abstract P2-12-26.

Solin LJ et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194. Proc SABCS 2011;Abstract S4-6.

Module 3: Advanced ER-Positive Disease

Atkins MB et al. Everolimus. Nat Rev Drug Discov 2009;8(7):535-6. Abstract

Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011;[Epub ahead of print]. Abstract

Hortobagyi GN et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 Phase III trial. Proc SABCS 2011;Abstract S3.7.

Mehta RS et al. A Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. Proc SABCS 2011;Abstract S1-1.

Module 4: HER2-Negative, BRCA1/2 Mutant Breast Cancer

Andreopoulou E et al. Randomized, double-blind, placebo-controlled Phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P885. Proc SABCS 2011;Abstract OT3-01-17.

Gradishar WJ et al. Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer: Overall survival and safety analysis of a randomized Phase 2 trial. Proc SABCS 2011;Abstract P5-19-03.

Miller KD et al. PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. Proc SABCS 2011;Abstract OT3-01-05.

Vahdat LT et al. Comparison of the incidence of peripheral neuropathy with eribulin mesylate versus ixabepilone in metastatic breast cancer patients: A randomized Phase II study. Proc SABCS 2011;Abstract P5-19-02.

Module 5: Bone-Targeted Therapy

De Boer R et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST. Proc SABCS 2011;Abstract S1-3.

Gnant M et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Proc SABCS 2011;Abstract S1-2.

Paterson AHG et al. NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy — Final analysis. Proc SABCS 2011;Abstract S2-3.